Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects

• المؤلفون الرئيسيون: Yuankui Zhu (مؤلف), Ke Wang (مؤلف), Linghe Yue (مؤلف), Dianbao Zuo (مؤلف), Junfeng Sheng (مؤلف), Sina Lan (مؤلف), Zilong Zhao (مؤلف), Shuang Dong (مؤلف), Sheng Hu (مؤلف), Xin Chen (مؤلف), Mingqian Feng (مؤلف)
• التنسيق: كتاب
• منشور في: Elsevier, 2024-05-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Chimeric antigen receptor (CAR)-modified T cell therapy has achieved remarkable efficacy in treating hematological malignancies, but it confronts many challenges in treating solid tumors, such as the immunosuppressive microenvironment of the solid tumors. These factors reduce the antitumor activity...